Indaptus Therapeutics Inc (INDP) Stock Price, Quote & News

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly kno...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 427 2727

Website: indaptusrx.com

Address:

Three Columbus Circle, 15th Floor, New York, United States

6monthinvester Nov. 15 at 5:45 PM

$INDP good high risk high reward

0 · Reply

ThatDudeWithNoMoney Nov. 13 at 1:14 PM

$THAR $IXHL $PSTV $INDP FDA NEWS!!! OPENING BELL RIPPER!!!

3 · Reply

TwongStocks Nov. 12 at 1:49 PM

$INDP Decoy20 trial paused. "The Safety Review Committee has reviewed all available safety data from this cohort and determined that the Decoy20 and tislelizumab combination appears to be tolerable at the current dose and schedule. While this safety data may support proceeding to full enrollment, we have paused enrollment pending additional efficacy evaluations of the remaining participants and to further assess our next development options."

1 · Reply

TwongStocks Nov. 12 at 1:47 PM

$INDP 10-Q https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315225021759/form10-q.htm • 1,751,163 share soutstanding as of Nov 11 • Increase in shares from Q2 primarily came from conversion of promissory notes (+501,566 shares) and use of the ATM (+520,000 shares).

0 · Reply

TwongStocks Nov. 12 at 1:35 PM

$INDP Q3 Financial results and corporate update https://www.globenewswire.com/news-release/2025/11/12/3186262/0/en/Indaptus-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html • Completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab. • July 2025, completed conversion of the promissory notes, that were issued in June 2025 for $5.7 million, into common stock, pre-funded warrants and warrants. • September 2025, strengthened balance sheet with $2.3 million raised through at-the-market facility. • As of September 30, the Company had cash and cash equivalents of approximately $5.8 million. The Company expects that its current cash and cash equivalents will support ongoing operating activities into the first quarter of 2026.

0 · Reply

AutoAZTrader Nov. 10 at 3:14 PM

$INDP Greenest day ever and this is red; pathetic.

0 · Reply

kiki64 Nov. 10 at 11:09 AM

$INDP POS losing deal!! What a waste of money.

1 · Reply

AverageAndy Nov. 8 at 9:37 PM

$INDP $300/share in 2030!!’

1 · Reply

AutoAZTrader Nov. 5 at 4:02 PM

$INDP Thirty cents from all-time-low. Jesus.

1 · Reply

AutoAZTrader Oct. 30 at 7:37 PM

$INDP Fucking dogshit.

0 · Reply

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 4, 2025, 4:01 PM EDT - 2 months ago

Indaptus Therapeutics Provides Clinical Update

Sep 2, 2025, 4:05 PM EDT - 2 months ago

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Aug 13, 2025, 8:00 AM EDT - 3 months ago

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 1, 2025, 8:14 AM EDT - 4 months ago

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Jun 25, 2025, 7:00 AM EDT - 5 months ago

Indaptus Therapeutics Announces Reverse Stock Split

Jun 13, 2025, 8:00 AM EDT - 5 months ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

May 14, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Mar 25, 2025, 8:00 AM EDT - 8 months ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Mar 20, 2025, 8:00 AM EDT - 8 months ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Mar 18, 2025, 8:00 AM EDT - 8 months ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Mar 13, 2025, 7:30 AM EDT - 8 months ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:15 PM EDT - 8 months ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 4, 2025, 8:00 AM EST - 9 months ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Feb 25, 2025, 8:00 AM EST - 9 months ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 5, 2025, 8:00 AM EST - 10 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Jan 8, 2025, 8:00 AM EST - 11 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Nov 22, 2024, 8:36 AM EST - 1 year ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 11, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 7, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 1 year ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 4, 2024, 7:30 AM EST - 1 year ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Feb 8, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Jan 4, 2024, 8:00 AM EST - 2 years ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Nov 6, 2023, 4:01 PM EST - 2 years ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 8:45 AM EDT - 2 years ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

May 11, 2023, 7:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 2 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 1, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Apr 20, 2023, 4:05 PM EDT - 2 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 19, 2023, 9:28 AM EDT - 2 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 13, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Feb 14, 2023, 8:00 AM EST - 2 years ago

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

Feb 7, 2023, 8:05 AM EST - 3 years ago

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

6monthinvester Nov. 15 at 5:45 PM

$INDP good high risk high reward

0 · Reply

ThatDudeWithNoMoney Nov. 13 at 1:14 PM

$THAR $IXHL $PSTV $INDP FDA NEWS!!! OPENING BELL RIPPER!!!

3 · Reply

TwongStocks Nov. 12 at 1:49 PM

1 · Reply

TwongStocks Nov. 12 at 1:47 PM

0 · Reply

TwongStocks Nov. 12 at 1:35 PM

0 · Reply

AutoAZTrader Nov. 10 at 3:14 PM

$INDP Greenest day ever and this is red; pathetic.

0 · Reply

kiki64 Nov. 10 at 11:09 AM

$INDP POS losing deal!! What a waste of money.

1 · Reply

AverageAndy Nov. 8 at 9:37 PM

$INDP $300/share in 2030!!’

1 · Reply

AutoAZTrader Nov. 5 at 4:02 PM

$INDP Thirty cents from all-time-low. Jesus.

1 · Reply

AutoAZTrader Oct. 30 at 7:37 PM

$INDP Fucking dogshit.

0 · Reply

StockFlips Oct. 30 at 6:57 PM

$INDP took the L here. Still watching

0 · Reply

DanielSmith310 Oct. 29 at 4:57 PM

$INDP exploring innovation; AITX exploring engagement — AI systems now linking law enforcement and public security seamlessly.

0 · Reply

Jonsbr Oct. 28 at 1:02 PM

$INDP Expectations indicate very positive news.👀🚀⏳🟢

0 · Reply

kim14e Oct. 28 at 12:39 AM

$INDP offering soon😂 Indaptus Therapeutics Advances Cancer Treatment with DECOY20 Clinical Study - TipRanks.com https://www.tipranks.com/news/company-announcements/indaptus-therapeutics-advances-cancer-treatment-with-decoy20-clinical-study

0 · Reply

kim14e Oct. 26 at 2:45 AM

$INDP Short squeeze is gone 😂😂😂😂

1 · Reply

StockFlips Oct. 26 at 1:38 AM

Here’s $INDP The pressure here is absolutely insane. I took a starter on this trend line.

0 · Reply

AutoAZTrader Oct. 22 at 7:22 PM

$INDP God, this is detached from the market.

0 · Reply

AutoAZTrader Oct. 21 at 5:30 PM

$INDP Everything's going up; why the fuck is this cratering now? Fucking piece of shit.

0 · Reply

AutoAZTrader Oct. 21 at 5:17 PM

$INDP Stop dropping; fucking piece of shit,

0 · Reply

KayleeJonesTrades Oct. 20 at 12:47 PM

$INDP Up a solid 37.73% on INDP and still holding strong, watching this shit climb higher with zero regrets.

0 · Reply

Buysellbkr Oct. 20 at 12:25 PM

$INDP someone's playing with it here

1 · Reply

StockFlips Oct. 18 at 4:23 PM

$SPRC need to stay over $4 for trend reversal confirmation! $INDP heating up🔥🫵

0 · Reply

Market Cap	2.78M
Revenue (ttm)	0.00
Net Income (ttm)	-15.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	39,300
Avg Vol	668,608
Day's Range	N/A - N/A
Shares Out	1.11M
Stochastic %K	8%
Beta	1.00
Analysts	Strong Sell
Price Target	$25.00